Suffering from High Blood Pressure (Hypertension)?
1. Newly diagnosed patients AND 2. patients currently taking high blood pressure medications (but not controlled?), AND 3. previously diagnosed patients (no HBP meds for 4 weeks) may qualify for this study.
If so, you may be eligible to participate in a clinical research study with Bystolic® (nebivolol) and Diovan (valsartan) or placebo (1 in 13 chance). The study medications have been been approved for use by the FDA for patients who have High Blood Pressure
This study is being done to evaluate the effects of a drug called nebivolol or valsartan in people with stage 1 or 2 hypertension, a condition where a person’s diastolic blood pressure is 90-110 mm Hg. This is a 13 clinic visit, approximate up to 16 week study. Weekly clinic visits are required to be performed in early morning (am) hours. This study will evaluate the safety and tolerability of the study drugs. In addition, this study aims to compare study medications to placebo to see if taking nebevolol/valsartan is better than taking a placebo.
You may be eligible if you:
o Are 18+ years old
o Have High Blood Pressure (bottom number range >90-<110 mmHg)
Are newly diagnosed with high blood pressure with a diastolic reading around >95 and <110 mmHg
Have been previously diagnosed with High Blood Pressure but have not taken HBP medication for 4 weeks. Need to have a diastolic (bottom) reading >95 and <110 mmHg
o Are not pregnant or breastfeeding
You do not have asthma or sleep apnea
You do not use NSAID pain medication more than 2x per week
If you participate, you may receive compensation
for time and travel up to $455.00.
Eligible participants will receive:
• Study drug or placebo
• Study-related medical exams/weekly Blood Pressure Monitoring
• Study-related laboratory tests
Complete the Inquiry Form to the right and submit OR contact the Research Staff in the clinic at:
PRO-Lone Peak Clinic/Draper UT: 801-816-3925 PRO-Exodus Healthcare Clinic/Magna UT: 801-250-6979
David B. Jack, MD, et al Brian K. Zehnder, MD, et al
